Diabetic gastroparesis - Pipeline Insight, 2021
This report can be delivered to the clients within 48 hours
DelveInsight’s, “Diabetic gastroparesis - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Diabetic gastroparesis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Diabetic gastroparesis: Overview
Diabetic gastroparesis refers to cases of the digestive condition gastroparesis that is caused by diabetes. The symptoms of gastroparesis vary in severity from person to person and may include any combination of the nausea and vomiting, heartburn, loss of appetite, weight loss, bloating, unstable blood sugar levels, gastroesophageal reflux and/or stomach spasms. Gastroparesis is more common in females than males, and in people who have had surgery around the esophagus, stomach, or small intestine, as surgery can affect the vagus nerve. The American College of Gastroenterology (ACG) guidelines for the diagnosis and management of Diabetic gastroparesis state that a combination of appropriate symptoms and signs, along with delayed gastric emptying in the absence of gastric outlet obstruction or ulceration, is required to establish the diagnosis of Diabetic gastroparesis. The treatments for Diabetic gastroparesis include nutritional assessment and dietary modifications, glycemic control, prokinetic agents and antiemetic agents.
'Diabetic gastroparesis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diabetic gastroparesis pipeline landscape is provided which includes the disease overview and Diabetic gastroparesis treatment guidelines. The assessment part of the report embraces, in depth Diabetic gastroparesis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic gastroparesis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Diabetic gastroparesis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Diabetic gastroparesis Emerging Drugs
Further product details are provided in the report
Diabetic gastroparesis: Therapeutic Assessment
This segment of the report provides insights about the different Diabetic gastroparesis drugs segregated based on following parameters that define the scope of the report, such as:
Diabetic gastroparesis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Diabetic gastroparesis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetic gastroparesis drugs.
Diabetic gastroparesis Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Diabetic gastroparesis - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Diabetic gastroparesis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Diabetic gastroparesis: Overview
Diabetic gastroparesis refers to cases of the digestive condition gastroparesis that is caused by diabetes. The symptoms of gastroparesis vary in severity from person to person and may include any combination of the nausea and vomiting, heartburn, loss of appetite, weight loss, bloating, unstable blood sugar levels, gastroesophageal reflux and/or stomach spasms. Gastroparesis is more common in females than males, and in people who have had surgery around the esophagus, stomach, or small intestine, as surgery can affect the vagus nerve. The American College of Gastroenterology (ACG) guidelines for the diagnosis and management of Diabetic gastroparesis state that a combination of appropriate symptoms and signs, along with delayed gastric emptying in the absence of gastric outlet obstruction or ulceration, is required to establish the diagnosis of Diabetic gastroparesis. The treatments for Diabetic gastroparesis include nutritional assessment and dietary modifications, glycemic control, prokinetic agents and antiemetic agents.
'Diabetic gastroparesis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diabetic gastroparesis pipeline landscape is provided which includes the disease overview and Diabetic gastroparesis treatment guidelines. The assessment part of the report embraces, in depth Diabetic gastroparesis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic gastroparesis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Diabetic gastroparesis R&D. The therapies under development are focused on novel approaches to treat/improve Diabetic gastroparesis.
This segment of the Diabetic gastroparesis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Diabetic gastroparesis Emerging Drugs
- Nimacimab: Bird Rock Bio
- NG101: Neurogastrx
Further product details are provided in the report
Diabetic gastroparesis: Therapeutic Assessment
This segment of the report provides insights about the different Diabetic gastroparesis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Diabetic gastroparesis
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Diabetic gastroparesis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Diabetic gastroparesis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetic gastroparesis drugs.
Diabetic gastroparesis Report Insights
- Diabetic gastroparesis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Diabetic gastroparesis drugs?
- How many Diabetic gastroparesis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diabetic gastroparesis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Diabetic gastroparesis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Diabetic gastroparesis and their status?
- What are the key designations that have been granted to the emerging drugs?
- Bird Rock Bio
- Neurogastrx
- Vanda Pharmaceuticals
- Takeda
- GlaxoSmithKline
- Theravance Biopharma
- PTC Therapeutics
- Nimacimab
- NG101
- Tradipitant
- TAK-906 Maleate
- Camicinal
- TD-1473
- Sepiapterin
Introduction
Executive Summary
Diabetic gastroparesis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Diabetic gastroparesis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Diabetic gastroparesis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Diabetic gastroparesis Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Tradipitant: Vanda Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
Nimacimab: Bird Rock Bio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Diabetic gastroparesis Key Companies
Diabetic gastroparesis Key Products
Diabetic gastroparesis- Unmet Needs
Diabetic gastroparesis- Market Drivers and Barriers
Diabetic gastroparesis- Future Perspectives and Conclusion
Diabetic gastroparesis Analyst Views
Diabetic gastroparesis Key Companies
Appendix
Executive Summary
Diabetic gastroparesis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Diabetic gastroparesis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Diabetic gastroparesis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Diabetic gastroparesis Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Tradipitant: Vanda Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
Nimacimab: Bird Rock Bio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Diabetic gastroparesis Key Companies
Diabetic gastroparesis Key Products
Diabetic gastroparesis- Unmet Needs
Diabetic gastroparesis- Market Drivers and Barriers
Diabetic gastroparesis- Future Perspectives and Conclusion
Diabetic gastroparesis Analyst Views
Diabetic gastroparesis Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Diabetic gastroparesis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Diabetic gastroparesis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Diabetic gastroparesis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Diabetic gastroparesis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
